Gilead Sciences Inc Stock
Gilead Sciences Inc Stock
There is an upward development for Gilead Sciences Inc compared to yesterday, with an increase of €1.82 (1.540%).
With 67 Buy predictions and not a single Sell prediction Gilead Sciences Inc is an absolute favorite of our community.
As a result the target price of 128 € shows a slightly positive potential of 6.83% compared to the current price of 119.82 € for Gilead Sciences Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Gilead Sciences Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Gilead Sciences Inc in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gilead Sciences Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | 1.540% | 5.550% | 3.794% | 16.693% | 13.016% | 63.912% | 98.641% |
| Incyte Corp. | -0.720% | 1.703% | 4.084% | 42.409% | 24.080% | 73.530% | 67.845% |
| IQVIA Holdings Inc. | -1.000% | 3.917% | 14.975% | 28.945% | 8.545% | 5.115% | -0.333% |
| Vertex Pharmaceuticals Inc. | -1.560% | 6.604% | 6.149% | 32.334% | 14.360% | 40.160% | 171.979% |
Comments
Gilead Sciences (GILD) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $170.00 price target on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "overweight" rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Show more
Ratings data for GILD provided by MarketBeat